Evidence map›Paper›PMID 31336012›Full record

Trial reportCancer science2019

Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study.

Shinsuke Iida, Takashi Watanabe, Morio Matsumoto, Kenshi Suzuki, Kazutaka Sunami, Tadao Ishida, Kiyoshi Ando, Takaaki Chou, Shuji Ozaki, Masafumi Taniwaki and 7 more

Open access · goldAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 15 institutions in 1 country.

Shinsuke IidaDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.ORCID https://orcid.org/0000-0002-4951-960X
Takashi WatanabeDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Morio MatsumotoDepartment of Hematology, National Hospital Organization Shibukawa Medical Center, Shibukawa, Japan.
Kenshi SuzukiDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Kazutaka SunamiDepartment of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
Tadao IshidaDepartment of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan.ORCID https://orcid.org/0000-0003-3219-3292
Kiyoshi AndoDepartment of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.
Takaaki ChouDepartment of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
Shuji OzakiDepartment of Hematology, Tokushima Prefectural Central Hospital, Tokushima, Japan.
Masafumi TaniwakiDivision of Hematology and Oncology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Naokuni UikeDepartment of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Hirohiko ShibayamaDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
Kiyohiko HatakeDepartment of Hematology and Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Koji IzutsuDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Takayuki IshikawaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Yoshihisa ShumiyaDepartment of Oncology Clinical Development Planning, Ono Pharmaceutical Co., Ltd, Osaka, Japan.
Kensei TobinaiDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
National Hospital Organization · JPTokyo National Hospital · JPJapanese Red Cross Medical Center · JPKobe City Medical Center General Hospital · JPKyoto Prefectural University of Medicine · JPNagoya City University · JPNational Hospital Organization Kyushu Cancer Center · JPNiigata Cancer Center Hospital · JPOno Pharmaceutical (Japan) · JPSapporo Medical University · JPThe Cancer Institute Hospital · JPThe University of Osaka · JPTokai University · JPTokushima Prefectural Central Hospital · JPToranomon Hospital · JP

Funding

Ono Pharmaceutical Co., Ltd
6 · The paper itself

Abstract

This multicenter, open-label phase 1/2 study evaluated single-agent carfilzomib in 50 heavily pretreated Japanese patients with relapsed/refractory multiple myeloma (median of five prior treatments). In phase 1, patients were dosed at three levels: 15, 20, or 20/27 mg/m

Indexed as

AgedAntineoplastic AgentsDose-Response Relationship, DrugDrug Administration ScheduleDrug Resistance, NeoplasmFemaleFollow-Up StudiesHumansJapanLeukopeniaMaleMaximum Tolerated DoseMiddle AgedMultiple MyelomaNeoplasm Recurrence, LocalNeutropeniaAntineoplastic AgentscarfilzomibOligopeptidescarfilzomibclinical trialhematopoiesisJapanesemultiple myeloma

Identifiers

PMID31336012
PMCPMC6726678
OpenAlexW2963039381

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.